-

Agilent to Present at Goldman Sachs and J.P. Morgan Healthcare Conferences

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the company will deliver presentations at the Goldman Sachs 14th Annual Healthcare CEOs Unscripted Conference and the J.P. Morgan 40th Annual Healthcare Conference. Both conferences will be webcast. Details are included below.

Goldman Sachs 14th Annual Healthcare CEOs Unscripted Conference
Date: Jan. 6, 2022
Time: 11 a.m. ET/8 a.m. PT
Presenting for Agilent:
Mike McMullen, Agilent chief executive officer
Bob McMahon, Agilent chief financial officer

J.P. Morgan 40th Annual Healthcare Conference
Date: Jan. 11, 2022
Time: 4:30 p.m. ET/1:30 p.m. PT
Presenting for Agilent:
Mike McMullen, Agilent chief executive officer

Links to join the webcast will be available in the "News & Events -- Events" portion of the Investor Relations section of Agilent’s website.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in the life sciences, diagnostics, and applied chemical markets, delivering insight and innovation toward advancing the quality of life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.32 billion in fiscal 2021 and employs 17,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn, Twitter and Facebook.

Contacts

INVESTOR CONTACT:
Parmeet Ahuja
+1 408 345 8948
parmeet_ahuja@agilent.com

MEDIA CONTACT:
Sarah Litton
+1 669 255 7696
sarah.litton@agilent.com

Agilent Technologies Inc.

NYSE:A
Details
Headquarters: Santa Clara, California, USA
CEO: Padraig McDonnell
Employees: 18000
Organization: PUB

Release Versions
$Cashtags
Hashtags

Contacts

INVESTOR CONTACT:
Parmeet Ahuja
+1 408 345 8948
parmeet_ahuja@agilent.com

MEDIA CONTACT:
Sarah Litton
+1 669 255 7696
sarah.litton@agilent.com

Social Media Profiles
More News From Agilent Technologies Inc.

Agilent Reports First-Quarter Fiscal Year 2026 Financial Results

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies, Inc. (NYSE: A) today reported revenue of $1.80 billion for the first quarter ended Jan. 31, 2026, representing growth of 7.0% reported and up 4.4% core(1) compared with the first quarter of 2025. First-quarter GAAP net income was $305 million, or $1.07 per share. This compares with $318 million, or $1.11 per share, in the first quarter of 2025. Non-GAAP(2) net income was $386 million, or $1.36 per share, during the quarter, compared wi...

Agilent to Participate in TD Cowen’s 46th Annual Health Care Conference

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that Chief Financial Officer Adam Elinoff and Head of Investor Relations Tejas Savant will participate in a fireside chat at TD Cowen’s 46th Annual Health Care Conference. The event is scheduled for 11:10 to 11:40 a.m. EST on Tuesday, March 3, 2026, in Boston, Massachusetts. A live audio webcast and replay of the presentation will be available through Agilent’s Investor Relations website. About Agilent Tec...

Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma (EOC)

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved PD-L1 IHC 22C3 pharmDx, Code SK006, as the only FDA-approved companion diagnostic indicated to aid in identifying patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (EOC), whose tumors express PD-L1 and who may be eligible for treatment with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy. PD-L1 IHC 22C3 pharm...
Back to Newsroom